Fast Decrease of Bleeding Time by Tranexamic Acid in Uremia

Thromb Haemost 2000; 83(05): 785
DOI: 10.1055/s-0037-1613909

Letters to the Editor

Schattauer GmbH

Diego Mezzano

¹From the Departments of Hematology-Oncology and Nephrology, School of Medicine, Catholic University of Chile, Santiago, Chile

,

Blanca Muñoz

¹From the Departments of Hematology-Oncology and Nephrology, School of Medicine, Catholic University of Chile, Santiago, Chile

,

Edgar Pais

¹From the Departments of Hematology-Oncology and Nephrology, School of Medicine, Catholic University of Chile, Santiago, Chile

,

Patricio Downey

¹From the Departments of Hematology-Oncology and Nephrology, School of Medicine, Catholic University of Chile, Santiago, Chile

,

Jaime Pereira

¹From the Departments of Hematology-Oncology and Nephrology, School of Medicine, Catholic University of Chile, Santiago, Chile

References
1 Steiner RW, Coggins C, Carvalho ACA. Bleeding time in uremia: a useful test to assess clinical bleeding. Am J Hematol 1979; 07: 107-17.
2 Mannucci PM. Hemostatic drugs. N Engl J Med 1998; 339: 245-53.
3 Mezzano D, Tagle R, Panes O, Pérez M, Downey P, Muñoz B, Aranda E, Barja P, Thambo S, González F, Mezzano S, Pereira J. Hemostatic disorder of uremia: the platelet defect, main determinant of the prolonged bleeding time, is correlated with indices of activation of coagulation and fibrinolysis. Thromb Haemost 1996; 76: 312-21.
4 Mezzano D, Panes O, Pais E, Tagle R, González F, Mezzano S, Barriga F, Pereira J. Tranexamic acid inhibits fibrinolysis, shortens the bleeding time and improves platelet function in patients with chronic renal failure. Thromb Haemost 1999; 82: 1250-4.